Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,778 across all filing types
Latest filing 2013-06-05 Investor Presentation
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Investor Presentation 2013
Investor Presentation Classification · 99% confidence The document text provides a detailed analysis of Evotec AG's financial performance for '1Q/13 results' (First Quarter 2013), including revenue figures, operating loss, cash flow, and confirmation of the 2013 guidance. It also includes a detailed pipeline overview, newsflow updates for 2Q/13, and financial tables comparing historical and estimated future performance (2009-2015E). This structure—quarterly results summary, outlook confirmation, and detailed pipeline/news updates—is characteristic of an analyst report or a research note summarizing recent company performance, rather than an official regulatory filing like a 10-K or an Earnings Release (ER) which typically contains only the company's official numbers. Since the document is an external analysis (indicated by the header 'Evotec AG' followed by a recommendation 'BUY' and analyst contact information at the end), and it focuses on periodic financial results and outlook, it best fits the category of an Investor Presentation (IP) or a detailed research report. Given the options, 'IP' (Investor Presentation) is the closest fit for a detailed, forward-looking analysis document provided by a third party, although 'MDA' (Management Reports) or 'ER' (Earnings Release) might be considered if it were the company's own document. However, the presence of analyst ratings ('Recommendation: BUY') strongly suggests this is a third-party research report. In the provided schema, there is no explicit 'Analyst Report' category. The document summarizes quarterly results and provides extensive forward-looking commentary and pipeline details, which aligns closely with the content of an Investor Presentation (IP) or a detailed Management Discussion & Analysis (MDA). Since it is an external analysis summarizing the 1Q results and outlook, 'IP' (Investor Presentation) is the most appropriate classification among the choices for a detailed, non-official financial/strategy overview.
2013-06-05 English
Evotec AG: Release according to Article 26a, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Total Voting Rights Announcement' and explicitly references 'Article 26a, Section 1 of the WpHG' (German Securities Trading Act). It states that the number of voting rights has changed due to the exercise of stock options, providing the new total number of voting rights as of May 31, 2013. This type of announcement, detailing changes in the total number of shares carrying voting rights, is a specific regulatory disclosure. Among the provided codes, 'Declaration of Voting Results & Voting Rights Announcements' (DVA) is the most appropriate fit for an official announcement regarding the total voting rights count, even though it is not the result of a specific vote, but rather a mandatory disclosure related to the capital structure affecting voting power.
2013-05-31 English
Investor Presentation 2013
Investor Presentation Classification · 99% confidence The document provides a detailed analysis of Evotec AG's financial performance for Q1 2013, including revenue, margins, net loss, R&D expenses, and liquidity. It also includes comparative historical data (2011, 2012) and forward-looking estimates (2013e, 2014e, 2015e) for key metrics like revenue, EBIT, and EPS. Furthermore, it discusses management outlook, strategic drivers, pipeline milestones (Janssen, Roche), and concludes with an investment recommendation ('Anlageurteil') and target price. This structure—quarterly review, detailed financial tables, strategic outlook, and analyst recommendation—is characteristic of an Equity Research Report or an Investor Presentation. Given the depth of financial analysis, historical comparison, and explicit analyst commentary/recommendation ('Montega AG – Equity Research 1'), it aligns best with an Investor Presentation (IP) or a detailed Management Discussion & Analysis (MDA) often embedded in a larger report. Since it contains forward-looking guidance confirmation and detailed pipeline updates typical for investor communication, 'Investor Presentation' (IP) is the most fitting category, although it shares characteristics with MDA. It is not a formal regulatory filing like 10-K or IR, nor is it just a short announcement (RPA).
2013-05-21 German
Regulatory Filings 2013
Regulatory Filings Classification · 95% confidence The document is a research publication authored by an analyst at DZ BANK AG regarding Evotec AG. It provides an analysis of the company's quarterly results, business model, pipeline, and investment recommendation ('Buy'). It is not a company-issued financial report, but rather an external equity research report. Among the provided categories, 'Regulatory Filings' (RNS) serves as the appropriate fallback for documents that do not fit into specific corporate filing categories like 10-K, IR, or ER, as this is an analyst report rather than a primary company filing. Q1 2013
2013-05-17 English
Evotec and Harvard University to collaborate on development of new class of antibacterials
Regulatory Filings Classification · 100% confidence The document is a press release dated May 16, 2013, announcing a research collaboration between Evotec AG and Harvard University regarding the development of new antibacterials. It details the scope of the agreement, quotes executives, and provides boilerplate information about both entities. This type of announcement, which details strategic partnerships, research milestones, or business developments outside of mandatory financial reporting (like 10-K, ER, or IR), typically falls under general corporate news or regulatory filings. Since it is a specific announcement of a strategic alliance rather than a general regulatory filing (RNS) or a specific financial report, and it doesn't fit any other category (like M&A, Capital Change, or Director Dealing), the most appropriate classification is Regulatory Filings (RNS) as a general corporate announcement, or potentially a specialized category if one existed for 'Partnership Announcement'. Given the provided list, RNS serves as the best fit for non-standard corporate news releases disseminated via services like DGAP.
2013-05-16 English
Evotec Q1 2013: Driving Innovation Efficiency
Earnings Release Classification · 100% confidence The document explicitly states it reports 'financial results and corporate updates for the first quarter of 2013' and provides detailed financial figures (Revenues, Operating loss, Liquidity) and operational progress for that period. This content structure aligns perfectly with a comprehensive report covering a period shorter than a year, which corresponds to an Interim/Quarterly Report (IR). Although it mentions a conference call, the primary content is the financial summary and operational review, not just an announcement of a report (RPA) or a transcript (CT). It is not the full Annual Report (10-K) as it covers only Q1. Q1 2013
2013-05-14 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.